Table 1.

Clinical data for the full group of 13 people with schizophrenia

DiagnosisSexAgeMedTypeDoseIQtPANSStPSStNSStGSStDISDIS
SZM39Aripiprazole2nd13395449122391
SZF38Clozapine2nd800100100202852154
PSM42Clozapine2nd7501015913143291
PSM53Clozapine2nd100089401291982
SZM36Olanzapine2nd200111427142181
PSM28Pipotiazine1st20010164112330143
SZM531509573162532111
SZM31Clozapine2nd80010063131832101
PSF43Quetiapine2nd140011755121726112
PSM30Clozapine2nd10001065812202691
PSM28Clozapine2nd500845392024143
PSM49Clozapine2nd1200866315163293
PSM50Olanzapine2nd200894771723101
Mean406419858.51217.928.610.51.8
SD9.2438.99.715.83.75.38.42.41.1
  • The following information is provided: diagnosis (SZ = schizophrenia; PS = paranoid schizophrenia), medication (Med), medication type (1st = first-generation antipsychotic; 2nd = second-generation antispsychotic), medication dose (chlorpromazine equivalent in mg/d), intelligence quotient (IQ/NART score), total scores for the entire PANSS test (tPANSS), total scores for the positive symptoms of the PANSS test (tPSS), total scores for the negative symptoms of the PANSS test (tNSS), total scores for the general symptoms of the PANSS test (tGSS), scores on a cognitive factor, which overlaps heavily with the concept of disorganization syndrome (tDIS), and scores for item P2 on the PANSS test, “conceptual disorganization” (DIS).